Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/8369
|
| Title: | The response of patients with epstein-barr virus - associated hemophagocytic lymphohistiocytosis to HLH-2004 protocol in the initial therapy |
| Authors: | My, LT;Lien, LB;Hung, NT;Thuong, TC;Tuan, NM;Nhan, NT;Thinh, LQ;Dao, NTH;Le, DTM;Tung, TT;Anh, NHM;Anh, TNK;Anh, PNL;Khanh, LTX;Huong, PLM;Van, LT;An, DTT;Su, IJ |
| Contributors: | Division of Infectious Diseases |
| Abstract: | Purpose: To determine the rate of response of patients with Epstein Barr virus(EBV)associated HLH (hemophagocytic lymphohistiocytosis) to HLH 2004 protocol, and to evaluate the courses of clinical signs as well as laboratory data during the first 8 weeks of therapy. Methods: This was a prospective case series report consisting of 13 patients younger than 16 years old, diagnosed with EBV associated HLH and admitted to the Children Hospital 1 in HCMC from August 1st, 2011 to May 31st, 2012. Results: Of these patients, 54% (7/13) were classified as response group, 23% (3/13) as non response group and 23% (3/13) as mortality group. The median (range) of EBV DNA loads in plasma of the mortality group, non response group and response group were respectively 7.3 x 107.2 copies/ml (7.0 – 7.3 x107.2 copies/ml), 6.9 x107.2 copies/ml (5.7 – 7.5 x107.2 copies/ml) and 5.0x107.2 copies/ml (2.7 – 7.3 x 107.2 copies/ml). Immunochemotherapy were used as followed: dexamethasone in 100% (13/13) cases, cyclosporine A in 100% (13/13) cases, etoposide in 46% (6/13) cases and IVIg in 76% (10/13) cases. In the mortality group, dexamethasone, cyclosporine A and IVIg were given in 100% (3/3) cases, but etoposide was not used for any patients. The median time of treatment in the mortality group was only 7 days (7 – 15 days), in the non response group was 273 days (203 – 287 days) and in the response group was 224 days (182 – 329 days). Ferritinemia and triglyceridemia returned to the normal range after the 4th week of treatment in the response group, but still remained at a high level until the 8th week of treatment in the non response group. The EBV DNA load of the response group was below the detection limit in the second week of treatment, but still high in the non response and the mortality group. |
| Date: | 2014-11 |
| Relation: | Pediatric Blood and Cancer. 2014 Nov;61(11):2134-2135. |
| Link to: | http://dx.doi.org/10.1002/pbc.25097 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1545-5009&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000342723300075 |
| Appears in Collections: | [蘇益仁(2002-2015)] 會議論文/會議摘要
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000342723300075.pdf | | 51Kb | Adobe PDF | 580 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
